Presenter: David Stamler, M.D., CEO of Alterity Therapeutics ...
Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program – – Positive feedback supports readiness for Phase 3 initiation with manufacturing scale ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale -- Effects seen on both daily function ...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program - - Positive feedback supports readiness for Phase 3 initiation with manufacturing ...
Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program – – Positive feedback supports readiness for Phase 3 initiation with manufacturing scale ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results